Literature DB >> 3806160

Screening for recurrent breast cancer--its effectiveness and prognostic value.

R Tomin, W L Donegan.   

Abstract

Performance of periodic follow-up examinations after mastectomy for breast cancer is standard practice, primarily for early detection and treatment of recurrence. This study was designed to determine whether this routine screening resulted in significant survival benefit for the patient. The medical records of 1,230 women treated for cure of invasive carcinoma of the breast were reviewed, and 248 cases of recurrence were identified for analysis. Only 36% of recurrences were discovered asymptomatically. Asymptomatic recurrence was associated with favorable biologic factors, ie, more frequent estrogen receptor (ER) positivity and initial node negative status, and survival was superior to that of others. This was particularly true for occult local recurrence. However, compliance with a present schedule of examinations did not confer superior survival. It was concluded that (1) routine screening after mastectomy detects few recurrences that are not already symptomatic, and (2) the superior survival associated with discovery of occult recurrence may result from the influences of lead time and length bias.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3806160     DOI: 10.1200/JCO.1987.5.1.62

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

1.  Decision Making Using Postoperative CEA and CA 15-3 for Detection of Breast Cancer Recurrence.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

2.  Clinical surveillance for early stage breast cancer: an analysis of claims data.

Authors:  M S Simon; M Stano; R K Severson; M S Hoff; D W Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

Authors:  Mikayel Mkrtichyan; Anahit Ghochikyan; Hayk Davtyan; Nina Movsesyan; Dmitry Loukinov; Victor Lobanenkov; David H Cribbs; Amanda K Laust; Edward L Nelson; Michael G Agadjanyan
Journal:  Cell Immunol       Date:  2011-05-12       Impact factor: 4.868

4.  Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial.

Authors:  F Kovner; O Merimsky; M Hareuveni; N Wigler; S Chaitchik
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care.

Authors:  L K Temple; E E Wang; R S McLeod
Journal:  CMAJ       Date:  1999-10-19       Impact factor: 8.262

6.  Surveillance of patients with breast cancer after curative-intent primary treatment: current practice patterns.

Authors:  Julie A Margenthaler; Emad Allam; Ling Chen; Katherine S Virgo; Udayan Mayur Kulkarni; Anand P Patel; Frank E Johnson
Journal:  J Oncol Pract       Date:  2011-12-13       Impact factor: 3.840

7.  The clinical course of lung metastases from breast cancer.

Authors:  O K Schlappack; M Baur; G Steger; C Dittrich; K Moser
Journal:  Klin Wochenschr       Date:  1988-09-01

8.  Continuity of the doctor/patient relationship during the routine follow-up of a breast cancer patient.

Authors:  K Holli; M Hakama
Journal:  Support Care Cancer       Date:  1993-09       Impact factor: 3.603

9.  An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology.

Authors:  M S Simon; M Hoff; M Hussein; S Martino; A Walt
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

10.  Follow-up may not be beneficial after treatment of grade 1 breast cancer.

Authors:  M Kontos; D Allen; D T Trafalis; G Jones; H Garmo; L Holmberg; H Hamed
Journal:  Br J Surg       Date:  2009-09       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.